Abdominal pain in quiescent inflammatory bowel disease
- 3 September 2020
- journal article
- research article
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 36 (1) , 93-102
Abstract
Objectives Inflammation is an important driver of abdominal pain in inflammatory bowel disease (IBD). However, some patients in remission still experience pain. We aimed to identify risk factors associated with abdominal pain in quiescent IBD (QP-IBD) and to characterize differences from patients with active disease experiencing pain (AP-IBD). Methods We performed a retrospective analysis utilizing data from our institution’s IBD Natural History Registry (January 1, 2015–August 31, 2018). Endoscopic evaluation, concurrent laboratory studies, and validated surveys were completed by participants. Demographic and clinical data were also abstracted. Results We recruited 122 patients with quiescent disease (65f:57 m; 93CD:26UC:3Indeterminate) for participation in this study, 74 (60.7%) had QP-IBD. QP-IBD patients were more likely to have anxiety/depression (71.6% vs. 25.0%, p < 0.001) or to use antidepressants (47.3% vs. 22.9%, p < 0.010), opiates (18.9% vs. 2.1%, p < 0.010), other pain medications (50.0% vs. 18.8%, p < 0.010), or corticosteroids (18.9% vs. 2.1%, p < 0.010). On logistic regression analysis, corticosteroid use, anxious/depressed state, and female gender were each independently associated with QP-IBD (p < 0.050 or less). Compared with AP-IBD patients (n = 110, 59f:51 m; 69CD:38UC:3Indeterminate), QP-IBD patients were more likely to use antidepressants (45.6% vs. 26.4%, p < 0.010). Platelet, white blood cell, C-reactive protein, and sedimentation rate levels were all less likely to be elevated in QP-IBD (all p < 0.050), though 44% exhibited pathological elevation in at least one. Discussion QP-IBD was independently associated with corticosteroid use, anxiety/depression, and female gender. Compared with AP-IBD, QP-IBD patients were more likely to use antidepressants and less likely to exhibit elevated inflammatory markers. However, many QP-IBD patients still demonstrated pathological elevation of these tests, demonstrating the need to develop new noninvasive screening methods for this condition.Keywords
Funding Information
- Peter and Marsha Carlino Early Career Professorship in Inflammatory Bowel Disease
- Margot E. Walrath Career Development Professorship in Gastroenterology
This publication has 37 references indexed in Scilit:
- Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activityScandinavian Journal of Gastroenterology, 2011
- Impact of pain on health-related quality of life in patients with inflammatory bowel diseaseWorld Journal of Gastroenterology, 2010
- Postinfectious Irritable Bowel SyndromeGastroenterology, 2009
- Pain and inflammatory bowel diseaseInflammatory Bowel Diseases, 2009
- Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsiaAlimentary Pharmacology & Therapeutics, 2009
- Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and AdultsGastroenterology, 2008
- The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2008
- Perceptual responses in patients with inflammatory and functional bowel diseaseGut, 2000
- Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 1992
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983